NCCN Guidelines Insights: Antiemesis, Version 2.2017
Michael Berger(University of British Columbia), Miranda Hughes(National Comprehensive Cancer Network), Eric Roeland(Harvard University), Lisle M. Nabell(Memorial Sloan Kettering Cancer Center), Georgiana Ellis(Seattle Cancer Care Alliance), Dawn Dolan(Moffitt Cancer Center), Charles L. Loprinzi(Mayo Clinic in Arizona), J N Aston(Seattle Cancer Care Alliance), David S. Ettinger(Johns Hopkins University), Steve Kirkegaard(Fox Chase Cancer Center), X. Cynthia(Washington University in St. Louis), Kim Noonan(Seattle Cancer Care Alliance), John F. Timoney(Roswell Park Comprehensive Cancer Center), Barbara Todaro(Seattle Cancer Care Alliance), Victoria Maurer(Seattle Cancer Care Alliance), Bridget Scullion(Dana-Farber Brigham Cancer Center), Dwight D. Kloth(Seattle Cancer Care Alliance), Ruth Lagman(Seattle Cancer Care Alliance), Lee S. Schwartzberg(Renown Health), Dorothy A. Shead(University of the Witwatersrand), Sally Barbour(Duke Medical Center), Susan G. Urba(University of Michigan), Hope S. Rugo(City of Hope), Eun Jeong Kim(Cancer Institute (WIA)), Dean Lim(Cleveland Clinic), Philip J. Bierman(Susan Thompson Buffett Foundation), Jason Bergsbaken(University of Wisconsin Carbone Cancer Center), Laura Boehnke Michaud(Seattle Cancer Care Alliance), Debra Brandt(Yale Cancer Center)
Cited by 250
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k